BBIO Stock Forecast 2025-2026
Distance to BBIO Price Targets
BBIO Price Momentum
10 Quality Stocks Worth Considering Now
Researching Bridgebio Pharma (BBIO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BBIO and similar high-potential opportunities.
Latest BBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, BBIO has a bullish consensus with a median price target of $52.00 (ranging from $36.00 to $95.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $35.96, the median forecast implies a 44.6% upside. This outlook is supported by 16 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Josh Schimmer at Cantor Fitzgerald, projecting a 164.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BBIO Analyst Ratings
BBIO Price Target Range
Latest BBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $53.00 |
| Mar 31, 2025 | Redburn Atlantic | Joshua Smith | Buy | Initiates | $50.00 |
| Mar 24, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $50.00 |
| Feb 21, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $52.00 |
| Feb 21, 2025 | Citigroup | David Lebowitz | Buy | Maintains | $49.00 |
| Feb 21, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $95.00 |
| Feb 13, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $49.00 |
| Feb 12, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $49.00 |
| Dec 23, 2024 | Evercore ISI Group | Cory Kasimov | Outperform | Maintains | $50.00 |
| Dec 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $49.00 |
| Nov 25, 2024 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $48.00 |
| Nov 25, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $45.00 |
| Nov 25, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $49.00 |
| Nov 15, 2024 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $45.00 |
| Oct 25, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $43.00 |
| Oct 17, 2024 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $46.00 |
| Oct 16, 2024 | Scotiabank | Greg Harrison | Sector Outperform | Initiates | $44.00 |
| Oct 3, 2024 | Oppenheimer | Leland Gershell | Perform | Initiates | $0.00 |
| Oct 2, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $43.00 |
| Sep 30, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $43.00 |
BridgeBio Pharma Inc. (BBIO) Competitors
The following stocks are similar to Bridgebio Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BridgeBio Pharma Inc. (BBIO) Financial Data
BridgeBio Pharma Inc. has a market capitalization of $6.70B with a P/E ratio of -12.5x. The company generates $221.90M in trailing twelve-month revenue with a -241.4% profit margin.
Revenue growth is +237.1% quarter-over-quarter, while maintaining an operating margin of -3,762.9% and return on equity of +36.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
BridgeBio Pharma Inc. (BBIO) Business Model
About BridgeBio Pharma Inc.
Develops transformative medicines for genetic diseases.
BridgeBio Pharma Inc. operates by discovering and developing drugs specifically targeting genetic disorders. The company collaborates with academic and research institutions to leverage advancements in genomics and biotechnology, focusing on areas like dermatology, oncology, cardiology, neurology, and endocrinology. Revenue is generated through partnerships, grants, and the eventual commercialization of its drug therapies.
Established to transform genetic research into medical solutions, BridgeBio is active in both early and late stages of drug development. Its emphasis on addressing rare genetic disorders positions it strategically within the biopharmaceutical market, catering to a growing demand for personalized medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
725
CEO
Dr. Neil Kumar Ph.D.
Country
United States
IPO Year
2019
Website
bridgebio.comBridgeBio Pharma Inc. (BBIO) Latest News & Analysis
Latest News
BridgeBio Pharma, Inc. will announce its Q1 financial results and program updates on April 29, 2025, after market close.
BridgeBio's upcoming Q1 financial results and program updates could influence stock performance, shape investor sentiment, and impact valuations in the biopharmaceutical sector.
BridgeBio Pharma's Attruby demonstrates a 42% mortality reduction in ATTR-CM. Early launch success and strong pipeline suggest potential for significant revenue growth, with a $300 price target.
BridgeBio Pharma's Attruby demonstrates significant efficacy and market potential, likely boosting revenue and market share, while a $300 price target reflects strong growth expectations.
BridgeBio Pharma approved equity grants of 77,652 shares in restricted stock units to 20 new employees, vesting over time, under its 2019 Inducement Equity Plan.
BridgeBio's equity grants signal growth and talent acquisition, potentially enhancing innovation. This could positively impact future performance and stock value, attracting investor interest.
BridgeBio Pharma reported significant clinical improvements in patients with transthyretin amyloid cardiomyopathy from its Phase 3 trial of acoramidis, presented at the ACC Annual Scientific Sessions.
BridgeBio's positive trial results for acoramidis in treating ATTR-CM could lead to regulatory approval, boosting stock value and attracting investment in innovative therapies for genetic diseases.
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
28 days agoBridgeBio's acoramidis showed 0% mortality in a Japanese Phase 3 study and significant benefits in the global ATTRibute-CM trial. BridgeBio will receive a $30M milestone from Alexion.
The successful Phase 3 study data for acoramidis indicates strong market potential, with significant mortality reduction and positive company milestones, potentially boosting investor confidence and stock value.
Japan's Ministry of Health has approved BridgeBio Pharma's acoramidis (Beyonttra) for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Approval of Beyonttra opens a new market for BridgeBio Pharma, potentially boosting revenue and stock value, especially in a niche but critical therapeutic area.
Frequently Asked Questions About BBIO Stock
What is BridgeBio Pharma Inc.'s (BBIO) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, BridgeBio Pharma Inc. (BBIO) has a median price target of $52.00. The highest price target is $95.00 and the lowest is $36.00.
Is BBIO stock a good investment in 2025?
According to current analyst ratings, BBIO has 16 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $35.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BBIO stock?
Wall Street analysts predict BBIO stock could reach $52.00 in the next 12 months. This represents a 44.6% increase from the current price of $35.96. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is BridgeBio Pharma Inc.'s business model?
BridgeBio Pharma Inc. operates by discovering and developing drugs specifically targeting genetic disorders. The company collaborates with academic and research institutions to leverage advancements in genomics and biotechnology, focusing on areas like dermatology, oncology, cardiology, neurology, and endocrinology. Revenue is generated through partnerships, grants, and the eventual commercialization of its drug therapies.
What is the highest forecasted price for BBIO BridgeBio Pharma Inc.?
The highest price target for BBIO is $95.00 from Josh Schimmer at Cantor Fitzgerald, which represents a 164.2% increase from the current price of $35.96.
What is the lowest forecasted price for BBIO BridgeBio Pharma Inc.?
The lowest price target for BBIO is $36.00 from at , which represents a 0.1% increase from the current price of $35.96.
What is the overall BBIO consensus from analysts for BridgeBio Pharma Inc.?
The overall analyst consensus for BBIO is bullish. Out of 18 Wall Street analysts, 16 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $52.00.
How accurate are BBIO stock price projections?
Stock price projections, including those for BridgeBio Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.